Clinical Trials
6
Active:0
Completed:6
Trial Phases
4 Phases
Phase 1:3
Phase 2:1
Phase 3:1
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (50.0%)Not Applicable
1 (16.7%)Phase 2
1 (16.7%)Phase 3
1 (16.7%)Bioequivalence Study in Healthy Chinese Subjects Comparing SP-01 (Granisetron Patch) Manufactured at Two Different Sites
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: SP-01 manufactured by Site K (SP-01-K, Transdermal patch contained granisetron)Drug: SP-01 manufactured by Site A (SP-01-A, Transdermal patch contained granisetron)
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Solasia Pharma K.K.
- Target Recruit Count
- 66
- Registration Number
- NCT05075876
- Locations
- 🇭🇰
Phase 1 Clinical Trials Centre, The University of Hong Kong, Hong Kong, Hong Kong
A Trial of Episil® Oral Liquid in Cancer Patients Suffering From Chemotherapy- and/or Radiation-induced Oral Mucositis
Not Applicable
Completed
- Conditions
- Chemotherapy- and/or Radiation-induced Oral Mucositis
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2018-06-08
- Lead Sponsor
- Solasia Pharma K.K.
- Target Recruit Count
- 60
- Registration Number
- NCT03546985
- Locations
- 🇨🇳
The People's Liberation Army 307 Hospital, Beijing, Beijing, China
🇨🇳Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
🇨🇳Tongji Hospital, Wuhan, Hubei, China
A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Phase 2
Completed
- Conditions
- Peripheral T-Cell Lymphoma
- Interventions
- Drug: SP-02L (darinaparsin for injection)
- First Posted Date
- 2016-01-13
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- Solasia Pharma K.K.
- Target Recruit Count
- 67
- Registration Number
- NCT02653976
A Randomized Controlled Trial of SP-01 (Granisetron Transdermal Delivery System) in Chemotherapy-induced Nausea and Vomiting
Phase 3
Completed
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- Drug: SP-01 (Granisetron Transdermal Delivery System)
- First Posted Date
- 2013-09-09
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Solasia Pharma K.K.
- Target Recruit Count
- 313
- Registration Number
- NCT01937156
- Locations
- 🇨🇳
The 81st Hospital of P.L.A., Nanjing, Jiangsu, China
A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea
Phase 1
Completed
- Conditions
- Peripheral T-cell Lymphoma
- Interventions
- Drug: SP-02L (darinaparsin for injection)
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2014-09-04
- Lead Sponsor
- Solasia Pharma K.K.
- Target Recruit Count
- 6
- Registration Number
- NCT01689220
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
- Prev
- 1
- 2
- Next
News
No news found